Skip to Content

'
Michelle A. Fanale, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

I have clinical and research interests in Hodgkin, T cell, Burkitt  lymphomas, & other c-MYC positive lymphomas, and HIV-associated lymphomas. Within these lymphoma subtypes I have a desire to develop new therapies which can first be evaluated in relapsed/refractory disease and then integrated into earlier lines of therapy both in combination with each other and with chemotherapy. I also wish to define best management strategies for the rarer disease presentations including for advanced stage and relapsed nodular lymphocyte predominant Hodgkin lymphoma, T cell lymphoma, and relapsed Burkitt and double-hit lymphomas. Through clinical trials I want to integrate translational research studies that will add to our understanding of mechanisms of lymphoma cell growth regulation and provide insights that will lead to improved methods of prognostication and combinations of therapies that target crucial pathways needed for lymphoma cell survival and proliferation.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 429
Houston, TX 77030
Phone: 713-792-2860
Fax: 713-794-5656

Education & Training

Degree-Granting Education

1999 University of Medicine and Dentistry, Newark, NJ, MD, MD
1994 Rutgers College, Rutgers University, New Brunswick, NJ, BA, Molecular Biology/Biochemistry and Psychology

Postgraduate Training

7/2002-6/2005 Medical Oncology and Hematology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert A. Wolff, M.D.
6/1999-6/2002 Internal Medicine Residency, Mayo Clinic, Rochester, MN, Henry J. Schultz, M.D.

Board Certifications

4/2013 Internal Medicine
2006 Hematology
2005 Medical Oncology

Experience/Service

Institutional Committee Activities

Member, Credentials Committee of the Medical Staff, 9/2010-1/2013
Member, Clinical Research Committee, 2006-2008

Professional Memberships

American Society of Clinical Oncology (ASCO)
Member, 2003-present
American Society of Hematology (ASH)
Member, 2007-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Adrada BE, Miranda RN, Rauch GM, Arribas E, Kanagal-Shamanna R, Clemens MW, Fanale M, Haideri N, Mustafa E, Larrinaga J, Reisman NR, Jaso J, You MJ, Young KH, Medeiros LJ, Yang W. Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Res Treat 147(1):1-14, 8/2014. e-Pub 7/2014. PMID: 25073777.
2. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study. J Clin Oncol. e-Pub 8/2014. PMID: 25135998.
3. Forero-Torres A, Bartlett NL, Berryman RB, Chen R, Matous JV, Fanale MA, O'Connor OA, Olshefski R, Smith SE, Huebner D, Levine PL, Grove LE, Gopal AK. Extended Treatment with Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-positive Hematological Malignancies. Leuk Lymphoma. e-Pub 8/2014. PMID: 25110824.
4. Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. (90) Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol. e-Pub 7/2014. PMID: 25040450.
5. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. e-Pub 7/2014. PMID: 25039868.
6. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. e-Pub 6/2014. PMID: 24943107.
7. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 4/2014. e-Pub 1/6/2014. PMID: 24386943.
8. Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J, O'Meara MM, Fanale MA. Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Lymphomas: A Retrospective Evaluation of Safety and Efficacy. Leuk Lymphoma. e-Pub 2/24/2014. PMID: 24359243.
9. Torres HA, Rallapalli V, Saxena A, Granwehr BP, Viola GM, Ariza-Heredia E, Adachi JA, Chemaly RF, Marfatia R, Jiang Y, Mahale P, Kyvernitakis A, Fanale MA, Mulanovich V. Efficacy and Safety of Antiretrovirals in HIV-Infected Patients with Cancer. Clin Microbiol Infect. e-Pub 2/2014. PMID: 24529214.
10. Fanale M, Assouline S, Kuruvilla J, Solal-Céligny P, Heo DS, Verhoef G, Corradini P, Abramson JS, Offner F, Engert A, Dyer MJ, Carreon D, Ewald B, Baeck J, Younes A, Freedman AS. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody Lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol 164(2):258-65, 1/2014. e-Pub 11/13/2013. PMID: 24219359.
11. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 1/2014. e-Pub 12/11/2013. PMCID: PMC3922714.
12. Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 7(1):24, 2014. e-Pub 3/2014. PMID: 24642247.
13. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 19(24):6882-6890, 12/15/2013. e-Pub 10/4/2013. PMID: 24097867.
14. Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 14(13):1348-56, 12/2013. e-Pub 11/15/2013. PMID: 24239220.
15. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 12/2013. e-Pub 10/1/2013. PMID: 24117234.
16. Arai S, Fanale M, DeVos S, Engert A, Illidge T, Borchmann P, Younes A, Morschhauser F, McMillan A, Horning SJ. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 54(11):2531-3, 11/2013. e-Pub 6/5/2013. PMID: 23617324.
17. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902-9, 9/2013. PMID: 23545991.
18. Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U. High-dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Biol Blood Marrow Transplant 19(6):991-4, 6/2013. PMID: 23507470.
19. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 4/2013. PMID: 23276888.
20. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 30(33):4161-7, 11/2012. PMID: 22965964.
21. Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies. Oncologist 17(8):1073-80, 8/2012. PMCID: PMC3425525.
22. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. J Clin Oncol 30(22):2776-82, 8/2012. PMID: 22753910.
23. Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, Fayad L, Fanale M, Romaguera J, Luong A, Kwak LW, Neelapu SS. TCL1: A Shared Tumor-associated Antigen for immunotherapy Against B-cell Lymphomas. Blood 120(8):1613-23, 8/2012. PMCID: PMC3429305.
24. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 7/2012. PMID: 22677155.
25. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 6/2012. PMID: 22015451.
26. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. J Clin Oncol 30(18):2190-6, 6/2012. PMID: 22614995.
27. Oki Y, Copeland A, Romaguera J, Fayad L, Fanale M, Faria Sde C, Medeiros LJ, Ivy P, Younes A. Clinical Experience with the Heat Shock Protein-90 inhibitor, Tanespimycin (17AAG), in Patients with Relapsed Lymphoma. Leuk Lymphoma 53(5):990-2, 5/2012. PMID: 21988665.
28. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 5/2012. PMCID: PMC3359733.
29. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119(9):2171-2, 3/2012. PMID: 22383790.
30. Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE. Gemcitabine, fludarabine and melphalan (G-FM) as a reduced-intensity conditioning regimen for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: preliminary results. Leuk Lymphoma 53(3):499-502, 3/2012. e-Pub 10/2011. PMID: 21859247.
31. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL. A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. Clin Cancer Res 18(1):248-255, 1/1/2012. e-Pub 11/11/2011. PMID: 22080439.
32. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell RE. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 12(13):1222-8, 12/2011. e-Pub 10/2011. PMID: 22033282.
33. Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 154(2):284-6, 7/2011. e-Pub 4/2011. PMID: 21517809.
34. Fanale MA, Younes A. Nodular lymphocyte predominant Hodgkin's lymphoma. Cancer Treat Res 142:367-81, 2008. PMID: 18283795.
35. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 67(3)(3):333-350, 2007. PMID: 17335294.
36. Pataer A, Fanale MA, Roth JA, Swisher SG, Hunt KK. Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53. Cancer Gene Ther 13(8):806-14, 8/2006. e-Pub 4/2006. PMID: 16628227.
37. Fanale MA, Uyei AR, Theriault RL, Adam K, Thompson RA. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 6(4):354-6, 10/2005. PMID: 16277887.
38. McKenzie T, Liu Y, Fanale M, Swisher SG, Chada S, Hunt KK. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu overexpressing breast cancer cells. Surgery 136(2):433-437, 8/2004. PMID: 15300212.
39. Petersen WO, Trapp MA, Fanale MA, Kaur JS. Evaluating the WEB training program for cancer screening in Native American women. Holist Nurs Pract 17(5):262-75, Sep-Oct, 9/2003. PMID: 14596376.
40. Fanale MA, Zeldenrust SR, Moynihan TJ. Some unusual complications of malignancies: case 2. Marantic endocarditis in advanced cancer. J Clin Oncol 19(19):4111-4114, 10/2002. PMID: 12351608.
41. Ricketts MH, Amsterdam JD, Park DS, Yang RS, Poretz RD, Zhang X, Fanale M, Baddoo A, Manowitz P. A novel arylsulfatase A protein variant and genotype in two patients with major depression. J Affect Disord 40(3):137-47, 10/1996. PMID: 8897113.
42. Dabaja B, Shihadeh F, Etzel C, Fu-Wen L, Shirvani S, Ballas L, Allen P, Rodriguez MA, Oki Y, Fanale M, Wogan C, and Younes A. Continuous Decline in Second Malignancies Occurring after Treatment of Hodgkin's Lymphoma: Analysis of 1670 Patients Seen Over a 50-year Period. Submitted.

Invited Articles

1. Fanale M. A novel prognostic scoring system for NLPHL. Blood 122(26):4154-5, 12/19/2013. PMID: 24357707.
2. Fanale M. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment? Hematology Am Soc Hematol Educ Program 2013:406-13, 2013. PMID: 24319212.

Editorials

1. Fanale, M. Hortobagyi, G. Bisphosphonates in the prevention and treatment of bone metastases. Oncology(17):1278-1280, 2003.

Abstracts

1. Oki, Y, Fanale, MA, Westin, JR, Fowler, N, Neelapu, SS, Hagemeister, FB, Rodriguez, MA, Younes, A. A Phase I Study Of Panobinostat In Combination With ICE (Ifosfamide, Carboplatin and Etoposide) In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (cHL). Blood (ASH Annual 2013 Meeting Abstract) 122(21), 12/2013.
2. Fanale, MA, Horwitz, SM, Forero-Torres, A, Bartlett, NL, Advani, RH, Pro, B, Chen, R, Davies, A, Illidge, T, Huebner, D, Kennedy, DA, Shustov, AR. Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas. Blood (ASH Annual 2013 Meeting Abstracts) 122(21), 12/2013.
3. Janku, F, Garrido-Laguna, I, Velez-Bravo, V, Falchook, GS, Subbiah, V, Hong, DS, Oki, Y, Westin, JR, Nunez, CA, Fayad, LE, Kwak, LW, Shpall, EJ, Wheler, JJ, Liang, W, Salhia, B, Meric-Bernstam, F, Kurzrock, R, Fanale, M. Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. Blood (ASH Annual Meeting Abstracts) 122(51), 12/2013.
4. Samaniego F, Wise J, Fayad L, Fanale M, Hagemeister F, Sevaraj V, Goldenberg D, Kwak L, Berkova Z. Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo. Blood (ASH Annual Meeting Abstract), 11/2012.
5. Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak L, Romaguera J, Fanale M, Fayad L, Orlowski R, Wang M, Turturro F, Oki Y, Lacerte L, and Samaniego F. Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a phase I/II study. Blood (ASH Annual Meeting Abstracts) 120(21) (#901), 11/2012.
6. Pro B, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T, Matous J, Ramchandren R, Fanale M, Connors J, Yang Y, Kennedy D, and Shustov A. Long-term remissions observed in an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21) (#2745), 11/2012.
7. Foerero A, Hamadani M, Fanale M, Bello C, Kipps T, Offner F, Verhoer G, Federic M, Gregory S, Sonet A, Assouline S, Oteyza J, Tomas J, Cuneo A, Zhang W, Goswani T, Ibrahim R, Yao Z, Herbst R, and Cheson B. MEDI-551, a humanized monoclonal anti-CD19, in adults with relapsed or refractory advanced B-cell malignancies: Results from a Phase I/II study. Blood (ASH Annual Meeting Abstracts) 120(21) (#3677), 11/2012.
8. Karaturi M, Arai S, Chen R, Gopal A, Feng L, Yuan Y, Smith S, Ansell S, Rosenblatt J, Savage K, Ramchandren R, Barlett N, Cheson B, Forero-Torress A, Moskowitz C, Connors J, Fanale M, de Vos S, Engert A, Illidge T, Borchmann P, Morschhauser F, Horning S, and Younes A. Overall survival benefit for patients with relapsed Hodgkin lymphoma treated with brentuximab vedotin after autologous stem cell transplant. Blood (ASH Annual Meeting Abstracts) 120(21) (#3701), 11/2012.
9. Westin J, Chu F, Fayad L, Kwak L, Fowler N, Romaguera J, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu S. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21) (#793), 11/2012.
10. Fanale M, Lai C, Rimes S, Ramirez M, Hagemeister F, Fowler N, Younes A, Fayad L, Rodriguez MA, Turturro F, Samaniego F, Romaguera J, Levin V, Horowitz S, Woolery J, and Milbourne A. Positive maternal-fetal outcomes with treatment of lymphoma during pregnancy: UT MD Anderson Cancer Center prospective experience. Blood (ASH Annual Meeting Abstracts) 120(21) (#3670), 11/2012.
11. Oki Y, Westin J, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak L, Romaguera J, Fanale M, Younes A, Rodriguez MA, Orlowski R, Wang M, Ouzounian S, Samaniego F, and Fayad L. R-HCVAD alternating with R-methotrexate cytarabine in younger patients (pts) with IH and high-risk age adjusted-IPI DLBCL. Blood (ASH Annual Meeting Abstracts) 120(21) (#3707), 11/2012.
12. Fanale M, Bartlett N, Forero-Torres A, Younes A, Chen R, Friedberg J, Matous J, Shustov A, Smith S, Zain J, O-Meara M, and Gopal A. Retrospective analysis of the safety and efficacy of brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30+ hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 120(21) (#3687), 11/2012.
13. Oki Y, Chuang H, Chasen B, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister FB, Rodriguez A, Neelapu S, Samaniego F, Kwak L, and Younes A. The prognositc value of interim PET scan in patients with classical Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21) (#1529), 11/2012.
14. Advani R, Fanale M, Kennedy D, Pro B. Resolution of Malignant Cutaneous Lesions with Brentuximab Vefotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (sALCL), 3/2012.
15. Advani, R, Shustov A, Matous J, Radhakrishnan Ramchandren R, Fanale M,Connors, J, Yang, YKennedy D andPro B. Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. Blood (ASH Annual Meeting Abstracts), 11/2011.
16. Vadhan-Raj S, Spasojevic I, Zhou X, Romaguera J, Fanale M, Fayad L, Fowler N, Huen A, Hagemeister F, Rodriguez A, Neelapu S, Samaniego F, Younes A, Kwak L. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, +/- Rituxan (R/CHOP): Randomized, Double-blind, Placebo-Controlled Study. Blood (ASH Annual Meeting Abstracts), 11/2011.
17. Fowler N, Neelapu S, Fanale M, Rodriguez M, Pro B, Hagemeister F, Younes A, Shah J, Kwak L, Rodriguez D, McLaughlin P. Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts), 11/2011.
18. Fanale M, Franklin A, Ramchandren R, Termuhlen A, Gopal AK, Shustov A, Kennedy D, Sievers E. Complete remissions observed in a subset of pediatric patients with CD30-Expressing malignant lymphomas treated in clinical studies of brentuximab vedotin (SGN-35). 2011 The European Multidisciplinary Cancer Congress, 9/2011.
19. Freedman A, Kuruvilla J, Assouline S, Engert A, Heo D, Solal-Celigny P, Corradini P, Verhoef G, Younes A, Bendiske J, Ewald B, Dey J, Baeck J, Bilic S, Rediske J, Fanale M. Anti-CD40 monoclonal antibody lucatumumab exhibits anti-tumor activity in follicular lymphoma and other lymphoma subtypes: Phase I/II preliminary findings. 11th International Conference on Malignant Lymphoma, 6/2011.
20. Shustov AR, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale MA, Connors JM, Yang Y, Sievers EL, Kennedy DA, Pro Bi. Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase 2 study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). 11th International Conference on Malignant Lymphoma, 6/2011.
21. Advani R, Forero-Torres A, Fanale M, Bartlett N, Rosenblatt J, Kennedy D, Sievers E, Younes A. Objective responses with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin Lymphoma (HL) who refused or were ineligible for autologous stem cell transplantation (ASCT). 16th Congress of the European Hematology Association, 6/2011.
22. Wang M, Fayad L, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Cabanillas F, Zhang L, Champlin R, Kwak L, Feng L, Bell N, Zeldis J, and Romaguera J. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in relapsed/refractory mantle cell lymphoma: a completed phase I/II clinical trial. 11th International Conference on Malignant Lymphoma 22(Suppl 4), 6/2011.
23. Romaguera J, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad L, Fowler N, Orlowski R, Feldman T, Wagner-Bartak N, Smith J, Ford P, Kwak L, and Goy A. Phase I-II study of bortezomib in combination with R-HCVAD and R-Methotrexate/cytarabine (R-MA) in untreated mantle cell lymphoma (MCL). 11th International Conference in Malignant Lymphoma, 6/2011.
24. Advani R, Fanale M, Kennedy D, Pro B. Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. American Academy of Dermatology 2012, 6/2011.
25. Pro B, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T, Matous J, Ramchadren R, Fanale M, Connors J, Yang Y, Sievers E, Kennedy D and Shustov A. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. 2011 T-Cell Lymphoma Forum, 1/2011.
26. Freedman A, Kuruvila J, Assouline S, Engert A, Heo D, Solal-Celigny P, Corradini P, Verhoef G, Fanale M, Bendiske J, Ewald B, Dey J, Baeck J, and Younes A. Clinical activity of lucatumumab (HCD122) in patients (pts) with relapsed/refractory Hodgkin or Non-Hodgkin lymphoma treated in a phase Ia/II clinical trial (NCT00670592). American Society Hematology Annual 2010 Meeting, 12/2010.
27. Shustov A, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T, Matous J, Ramchadren R, Fanale M, Connors J, Yang Y, Sievers E, Kennedy D, and Pro B. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. American Society Hematology Annual 2010 Meeting, 12/2010.
28. Fanale M, Lai C, McLaughlin P, Romaguera J, Fayad L, Hagemeister F, Samaniego F, Rodriguez M, Neelapu S, Shah J, Kwak L, Dong W, Reed V, Dabaja B, Popat U, and Younes A. Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. American Society Hematology Annual 2010 Meeting, 12/2010.
29. Younes A, Fanale M, McLaughlin P, Copeland A, Zhu J, and de Castro S. Phase I study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: Evidence of clinical and biologic activity in multiple lymphoma subtypes. American Society Hematology Annual 2010 Meeting, 12/2010.
30. Younes A, Copeland A, Fanale M, Hagemeister F, Fayad L, Pro B, Faria S, Ji Y, Medeiros J, Berry D, and Buglio D. Phase I/II study of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and Non-Hodgkin lymphoma. American Society Hematology Annual 2010 Meeting, 12/2010.
31. Vadhan-Raj S, Hagemeister F, Fayad L, Zhou X, O'Roark S, Ames K, Rodriguez M, Fanale M, Pro B, Johnson M, McLaughlin P, Bueso-Ramos C, Younes A, Kwak L, and Romaguera J. Randomized, double-blind, placebo-controlled, dose and schedule-finding study of AMG 531 in chemotherapy-induced thrombocytopenia (CIT): Results of a phase I/II study. American Hematology Society Annual 2010 Meeting, 12/2010.
32. Fanale M, Fayad L, Kwak L, Liboon MJ, Horowitz S, Nieto Y, Anderlini P, Popat U, and Younes A. A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus ICE for Patients with Relapsed or Refractory Hodgkin Lymphoma. 8th International Symposium on Hodgkin Lymphoma (#94), 10/2010.
33. Fanale M, Vigil K, Nieto Y, Younes A, and Mulanovich V. Increased Risk of Infectious Complications in HIV Patients with Advanced Stage and Relapsed Hodgkin Lymphoma. 8th International Symposium on Hodgkin Lymphoma (#95), 10/2010.
34. Fowler N, McLaughlin P, Hagemeister FB, Kwak LW, Fanale, MA Neelapu SS, Fayad L, Orlowski RZ, Wang M, and Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. ASCO Meeting Abstracts 2010 28(15 Suppl):8036a, 5/2010.
35. Fowler N, McLaughlin P, Hagemeister F, Kwak L, Fanale M, Neelapu S, Fayad L, Pro B, Sergent C, White S, Samaniego F. A biologic combination of lenalidomide and rituximab for frontline therapy of indolent B-cell non-Hodgkin's lymphoma. American Society Hematology Annual 2009 Meeting 114(22):683, 11/2009.
36. Wang M, Fayad L, Hagemeister F, Neelapu S, Samaniego F, McLaughlin P, Samuels b, Yi Q, Pro B, Fanale M, Shah J, Younes A, Bell N, Knight R, Zeldis J, Kwak L, Romaguera J. A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma. American Society Hematology Annual 2009 Meeting 114(22):1064, 11/2009.
37. Popat U, Hosing C, Fanale M, Medeiros J, Alousi A, Giralt S, de Lima M, Qazilbash M, Kebriaei P, Younes A, Khouri I, Anderson B, Champlin R, Anderlini P. Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). American Society Hematology Annual 2009 Meeting 114(22):912, 11/2009.
38. Westin J, Thompson M, Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone loss in frontline lymphoma patients: urine Ntx and bone specific alkaline phosphatase provide early evidence of zoledronic acid activity. American Society Hematology Annual 2009 Meeting 114(22):1508, 11/2009.
39. Younes A, Gordon L, Kim S, Romaguera J, Copeland A, Faria S, Kwak L, Fayad L, Hagemeister F, Fanale M, Lambert J, Bagulho T, Morariu-Zamfir R. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). American Society Hematology Annual 2009 Meeting 114(22):243, 11/2009.
40. Fanale M, Bartlett N, Forero-Torres A, Rosenblatt J, Horning S, Thompson S, Franklin A, Sievers EL, Kennedy DA. The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study. American Society Hematology Annual 2009 Meeting 114(22):1068, 11/2009.
41. Fanale M, Stiff P, Noonan K, McCoy J, Rustein M, and Moskowitz C. Safety and efficacy of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: results from an open-label dose and schedule-finding study. European Journal of Cancer Supplements 7(2):562, 9/2009.
42. Bartlett, N.L., Forero-Torres, A., Rosenblatt, J., Fanale, M., Horning, S., Thompson, S., Kennedy, D., Sievers, E. Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin Lymphoma (HL) or anaplastic large cell lymphoma (ALCL). J Clin Oncol 2009 Annual ASCO Proceedings (Post-Meeting Edition) 27(15S):Suppl 1 (#8500), 5/2009.
43. Fowler, N.H., McLaughlin, P., Kwak, L., Hagemeister, F., Fanale, M., Fayad, L., Pro, B., Samaniego, F. Lenalidomide and Rituximab for untreated indolent B cell non-Hodgkin lymphoma. J Clin Oncol 2009 Annual ASCO Meeting Proceedings (Post Meeting Edition) 27(15S):Suppl 1 (#8548), 5/2009.
44. McLaughlin, P., Neelapu, S., Fanale, M., Rodriguez, D., Ayala, A., Pro, B., Hagemeister, F. B., Younes, A., Neel, S., Fowler, N., Hess, M., Kwak, L. R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma. American Society of Hematology Annual 2008 Meeting(3056). e-Pub 12/2008.
45. Fanale, M., Burris, H., Yee, L., Luca, J., Dimick, K., Goldwasser, M., Novotny, W., Bray, G. Final results of a Phase Ib study of recombinant human Apo2L/TRAIL with rituximab in patients with relapsed low-grade NHL. 10th International Conference on Malignant Lymphoma(258), 6/2008.
46. Samaniego, F., Fanale, M., Pro, B., Hagemeister, F., McLaughlin, P., Romaguera, J., Neelapu, S., Younes, A., Kwak, L. Pentostatin Combined with Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B Cell Lymphoma. 10th International Conference of Malignant Lymphoma(334), 6/2008.
47. Fanale, M.A., Fayad, L., Pro, B., Samaniego, F., Zachariah, G., Nunez, C.A., Ji, Y., Younes. A phase I study of bortezomib in combination with ICE (BICE) in patients with relapsed/refractory classical Hodgkin lymphoma. American Society of Hematology Annual 2008 Meeting(3048), 2008.
48. Rodriguez, M.A., Fanale, M., Hagemeister, F.B., McLaughlin, P., Pro, B., Romaguera, J., Kwak, L., Fayad, L.E., Durand, J. Activity and toxicity of pegylated liposomal doxorubicin (DRCOP) for patients >60 years old with untreated diffuse large B cell lymphoma (DLBCL) : A phase II study. Journal of Clinical Oncology 26(15S/20505), 2008.
49. Huen, A., DeAngelo, D., Fanale, M., Vadhan-Raj, S. Pharmacokinetic analysis of two dose levels of rasburicase in adult patients with hematologic malignancies at high or potential risk for tumor lysis syndrome. Journal of Clinical Oncology 26(15S/14545), 2008.
50. Samaniego F., Fanale M., Pro B. Hagemeister F., McLaughlin P., Romaguera J., Neelapu F., Rodriguez A., Fayad L., Younes A., Beasley G., Kwak L. A Phase II trial of pentostatin combined with cyclophosphamide, and rituximab (PCR) for indolent B-cell lymphoma, American Society of Hematology. Annual 2007 Meeting, 11/2007.
51. Younes A., Pro, B., Fanale M., McLaughlin P., Neelapu S., Fayad L., Wedgwood A., Buglio D., Patterson T., Dubay M., Zuomei L., Martell R., Ward M., Bociek R. Isotype-selective HDAC inhibitor MGCD0103 decreases. Blood 110(2566), 11/2007.
52. Rodriguez M.A., Fanale M., Hagemeister F., McLaughlin P., Pro B., Romaguera J., Kwak L., Fayad L., Huang X., Durand J.B. Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients > 60 years old with untreated diffuse large B cell lymphoma (DLBCL). Blood 110(4468), 11/2007.
53. Fanale M., Fayad L., Pro B., Samaniego F., Zachariah G., Ji Y., Younes A. Safety and efficacy of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory classical Hodgkin Lymphoma. Blood 110(4506), 11/2007.
54. Yee L., Fanale M., Dimick K., Calvert S., Robins C., Ing J., Ling J., Novotny W., Ashkenazi A., Burris III H. A Phase IB safety and pharmacokinectic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. American Society of Clinical Oncology 25(2078), 2007.
55. Younes A, Fanale M., Pro B., McLaughlin P., Neelapu S., Fayad L.,. A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. American Society of Clinical Oncology 25(8000), 2007.
56. Gilliam M., Fanale M., Patterson C. Effectiveness of gonadotropin-releasing hormone agonists in prevention of ovarian failure in Hodgkin lymphoma: Update on current practice and review of literature. 7th International Symposium on Hodgkin Lymphoma 95(55):056, 2007.
57. Gilliam M., Wedgwood A., Fanale M. Effectiveness of lamivudine in the prevention of hepatitis B reactivation in patients receiving rituximab. Pan Pacific Lymphoma Conference, 2007.
58. Fanale M., Fayad, L.E., Romaguera J.E., McLaughlin P., Hagemeister. Experience with R-CHOP in patients with lymphocyte predominant Hodgkin lymphoma (LPHL). 7th International Symposium on Hodgkin Lymphoma 92(55):077, 2007.
59. Samaniego F, Fayad L. E. Pro M., McLaughlin P., Rodriguez M.A., Hagemeister F.B., Fanale M., Neelapu S., Younes A., Kwak L.W. Pentostatin combined with cyclophosphamide, and rituximab induces high response rates in patients with untreated indolent B-cell lymphoma. Blood 108(4722), 2006.
60. Younes A., Fayad L., Goy A., McLaughlin P, Pro B., Romaguera J, Hagemeister F., Rodriguez M.A., Samaniego F., Kwak L., Neelapu S., Medeiros L.J., Wedgwood A., Fanale M. Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups. Blood 108(2742), 2006.
61. Fanale M., Vorburger S., Liu Y., McKenzie T., Swisher S., Hunt K. AdhTERT-E2F-1 can induce selective apoptosis of breast cancer cells through multiple mechanisms. American Association of Cancer Research 46(2834), 2005.
62. McKenzie T.S., Lui Y., Keyomarsi K., Holzen U.V., Suh, Y., Fanale M., Swisher S., Chada S., and Hunt K. Associated gene-7 (Ad-mda7) regulated the Wnt signaling pathway in breast cancer cells. American Association of Cancer Research:871, 2005.
63. Fanale M., Liu Y., McKenzie T., Fokt I., Priebe W., Hunt K. Investigation of whether expression of bcl-2 influences the apoptotic response of doxorubicin-resistant breast cancer cells to a novel anthracycline. American Society of Clinical Oncology 24(2082), 2005.
64. Fanale M., Liu Y., McKenzie T., Fokt I., Priebe W., Hunt K. A novel anthracycline highly apoptotic in breast cancer cells. American. American Association of Cancer Research 45(3843), 2004.
65. McKenzie T., Liu Y., Fanale M., Swisher S., Chada S., Hunt K. Combination therapy of Ad-mda7 and trastuzumab inhibits tumor growth in nude mice and increase apoptosis in Her-2/neu overexpressing breast cancer cells. American Association of Cancer 45(5135), 2004.
66. Fanale M., Liu Y., McKenzie T., Fokt I., Priebe W., and Hunt K. Experimental and molecular therapeutics 35: preclinical models/pharmacology/mechanisms. American Association of Cancer Research:887, 2004.
67. Liu Y., McKenzie T., Fanale M., Swisher S., Chada S., Hunt K. Increased apoptosis in Her-2/neu overexpressing breast cancer cells by combination of Ad-mda7 and Herceptin. American Association of Cancer Research 45(4402), 2004.
68. Fanale M., Liu Y., McKenzie T., Vorburger S., Swisher S., Theriault R., Hunt K. Utility of hTERT-driven overexpression of E2F-1 to induce selective apoptosis of human breast cancer cells. American Society of Clinical Oncology 23(3158), 2004.

Book Chapters

1. Fanale M, Younes A. Diagnosis and treatment of lymphocyte predominant Hodgkin lymphoma. In: Rare Hematological Malignancies. Ed(s) Springer. Springer, 2007.
2. Fanale M, Buzdar A. Treatment of early-stage, locally advanced, and inflammatory breast cancer. In: MDACC: Medical Oncology, A Comprehensive Review, First. Ed(s) McGraw-Hill, 2007.
3. Fanale M, Dabaja B, Popat U, Anderlini P, Younes A. Hodgkin Lymphoma. In: Sixty Years of Survival Outcomes at the University of Texas MD Anderson Cancer Center. Submitted.

Grant & Contract Support

Title: Soluble CD30 As a Predictor of Treatment Response in Hodgkin Lymphoma
Funding Source: Texas Federation of Business and Professional Women
Role: Principal Investigator
Duration: 7/1/2006 - 6/2013

Last updated: 8/28/2014